Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Carisma Therapeutics Inc. (SESN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "CARISMA THERAPEUTICS INC. Unaudited Consolidated Balance Sheets June 30, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 76,353 $ 24,194 Marketable securities 40,725 27,802 Prepaid expenses and other assets 5,122 2,596 Total current assets 122,200 54,592 Property and equipment, net 7,590 8,628 Right of use assets – operating leases 3,047 4,822 Restricted cash 30 — Deferred financing costs 146 4,111 Total assets $ 133,013 $ 72,153 Liabilities, Convertible Preferred Stock and Stockholders' Equity Current liabilities: Accounts payable $ 2,487 $ 1,728 Accrued expenses 9,614 10,361 Deferred revenue 1,416 2,459 Operating lease liabilities 2,486 3,437 Finance lease liabilities 1,215 1,162 Other current liabilities 755 523 Total current liabilities 17,973 19,670 Deferred ..."
06/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "An amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 350,000,000 was approved",
"CARISMA THERAPEUTICS INC. AMENDED AND RESTATED 2014 STOCK INCENTIVE PLAN"
05/16/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/12/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "    AMENDED AND RESTATED OPEN MARKET SALE AGREEMENT SM   May 12, 2023",
"Letter re: Prospectus Supplement to Registration Statement on Form S-3"
05/12/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/12/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
05/12/2023 8-K Quarterly results
Docs: "CARISMA THERAPEUTICS INC. Unaudited Consolidated Balance Sheets March 31, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 62,777 $ 24,194 Marketable securities 76,190 27,802 Prepaid expenses and other assets 5,535 2,596 Total current assets 144,502 54,592 Property and equipment, net 8,107 8,628 Right of use assets – operating leases 3,493 4,822 Restricted cash 30 — Deferred financing costs — 4,111 Total assets $ 156,132 $ 72,153 Liabilities, Convertible Preferred Stock and Stockholders' Equity Current liabilities: Accounts payable $ 4,614 $ 1,728 Accrued expenses 10,187 10,361 Deferred revenue 2,136 2,459 Operating lease liabilities 2,597 3,437 Finance lease liabilities 1,188 1,162 Other current liabilities 755 523 Total current liabilities 21,477 19,670 Deferred ..."
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/03/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/03/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/17/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/17/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
04/17/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
04/04/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
04/04/2023 8-K/A Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Consent of Independent Registered Public Accounting Firm",
"Carisma Therapeutics Inc. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Consolidated Financial Statements Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets, December 31, 2022 and 2021 F-3 Consolidated Statements of Operations and Comprehensive Loss, Years Ended December 31, 2022 and 2021 F-4 Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit, Years ended December 31, 2022 and 2021 F-5 Consolidated Statements of Cash Flows, Years ended December 31, 2022 and 2021 F-6 Notes to Consolidated Financial Statements F-7 F- 1 Report of Independent Registered Public Accounting Firm",
"MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS",
"UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On March 7, 2023, Sesen Bio consummated the merger with Carisma in accordance with the terms of the Agreement and Plan of Merger Reorganization, dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 by and among Carisma and Seahawk Merger Sub, Inc. , pursuant to which, among other matters, Merger Sub merged with and into Carisma, with Carisma continuing as a wholly-owned subsidiary of Sesen Bio and the surviving corporation of the Merger. At which time, Sesen Bio changed its name to “Carisma Therapeutics Inc” . Immediately prior to the execution and delivery of the Merger Agreement, Carisma entered into a subscription ...",
"Carisma Therapeutics Reports Fiscal 2022 Financial Results and Recent Business Highlights"
03/22/2023 SC 13D/A HealthCap VII, L.P. reports a 8.4% stake in CARISMA THERAPEUTICS INC.
03/17/2023 SC 13D TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA reports a 5.4% stake in Carisma Therapeutics Inc.
03/16/2023 SC 13G Longview Innovation Corp. reports a 7.2% stake in Carisma Therapeutics Inc.
03/13/2023 SC 13G ModernaTX, Inc. reports a 12.6% stake in CARISMA THERAPEUTICS INC.
03/09/2023 SC 13D HealthCap VII, L.P. reports a 8.9% stake in CARISMA THERAPEUTICS INC.
03/06/2023 425 Form 425 - Prospectuses and communications, business combinations:
03/06/2023 8-K Other Events  Interactive Data
03/02/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF SESEN BIO, INC.",
"Sesen Bio Stockholders Approve Merger with Carisma Therapeutics Declares Special Dividend in the Aggregate of"
02/28/2023 425 Form 425 - Prospectuses and communications, business combinations:
02/28/2023 10-K Annual Report for the period ended December 31, 2022
02/28/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results Sesen Bio Board Believes the Pending Merger with Carisma"
02/27/2023 425 Form 425 - Prospectuses and communications, business combinations:
02/27/2023 425 Form 425 - Prospectuses and communications, business combinations:
02/27/2023 8-K Other Events  Interactive Data
02/22/2023 425 Form 425 - Prospectuses and communications, business combinations:
02/14/2023 425 Form 425 - Prospectuses and communications, business combinations:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy